OBJECTIVES: To evaluate the association between metastasis-inducing protein S100A4 and disease activity in patients with RA, and to demonstrate the effect of TNF-alpha blocking therapy on plasma levels of S100A4 in these patients. METHODS: Plasma levels of the S100A4 protein were analysed in 40 anti-TNF-alpha naive patients with active RA. Of the 40 patients, 25 were treated with adalimumab and monitored over time. The conformational form of S100A4 was analysed using size-exclusion gel chromatography. TNF-alpha mRNA expression and protein synthesis were analysed by RT-PCR and ELISA, respectively. RESULTS: Baseline levels of S100A4 were significantly correlated with disease activity in RA patients (r = 0.41; P < 0.01). After 12 weeks of treatment with adalimumab, there was an obvious shift in the conformations of S100A4 from the multimeric to the dimeric forms, whereas the total levels of the S100A4 protein remained unchanged. This suggests that the bioactive (multimer) S100A4 may decline in response to successful treatment with adalimumab. In addition, we showed significant up-regulation of TNF-alpha mRNA (P < 0.01), and protein release to the cell culture medium of monocytes stimulated with the S100A4 multimer compared with those treated with the dimer and to the unstimulated monocytes (P < 0.001). CONCLUSIONS: This is the first study to show that the levels of the S100A4 protein are correlated with RA disease activity. Furthermore, only the bioactive form, but not the total amount of S100A4, decreases after successful TNF-alpha blocking therapy in patients with RA. These data support an important role for the S100A4 multimer in the pathogenesis of RA.

Institute of Rheumatology Connective Tissue Research Laboratory Na Slupi 4 Prague

000      

04064naa a2200649 a 4500

001      

bmc12009153

003      

CZ-PrNML

005      

20140730105829.0

008      

120319s2009 xxk eng||

009      

AR

040    __

$d ABA008 $a ABA008 $b cze

041    0_

$a eng

044    __

$a xxk

100    1_

$a Andrés Cerezo, Lucie $7 xx0143527 $u Institute of Rheumatology Connective Tissue Research Laboratory, Na Slupi 4, Prague 2

245    10

$a Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis / $c L. Oslejskova, M. Grigorian, H. Hulejova, J. Vencovsky, K. Pavelka, J. Klingelhofer, S. Gay, M. Neidhart, H. Brabcova, D. Suchy, L. Senolt

520    9_

$a OBJECTIVES: To evaluate the association between metastasis-inducing protein S100A4 and disease activity in patients with RA, and to demonstrate the effect of TNF-alpha blocking therapy on plasma levels of S100A4 in these patients. METHODS: Plasma levels of the S100A4 protein were analysed in 40 anti-TNF-alpha naive patients with active RA. Of the 40 patients, 25 were treated with adalimumab and monitored over time. The conformational form of S100A4 was analysed using size-exclusion gel chromatography. TNF-alpha mRNA expression and protein synthesis were analysed by RT-PCR and ELISA, respectively. RESULTS: Baseline levels of S100A4 were significantly correlated with disease activity in RA patients (r = 0.41; P < 0.01). After 12 weeks of treatment with adalimumab, there was an obvious shift in the conformations of S100A4 from the multimeric to the dimeric forms, whereas the total levels of the S100A4 protein remained unchanged. This suggests that the bioactive (multimer) S100A4 may decline in response to successful treatment with adalimumab. In addition, we showed significant up-regulation of TNF-alpha mRNA (P < 0.01), and protein release to the cell culture medium of monocytes stimulated with the S100A4 multimer compared with those treated with the dimer and to the unstimulated monocytes (P < 0.001). CONCLUSIONS: This is the first study to show that the levels of the S100A4 protein are correlated with RA disease activity. Furthermore, only the bioactive form, but not the total amount of S100A4, decreases after successful TNF-alpha blocking therapy in patients with RA. These data support an important role for the S100A4 multimer in the pathogenesis of RA.

590    __

$a bohemika - dle Pubmed

650    02

$a dospělí $7 D000328

650    02

$a monoklonální protilátky $x terapeutické užití $7 D000911

650    02

$a humanizované monoklonální protilátky $7 D061067

650    02

$a antirevmatika $x terapeutické užití $7 D018501

650    02

$a revmatoidní artritida $x farmakoterapie $x krev $7 D001172

650    02

$a biologické markery $x krev $7 D015415

650    02

$a kultivované buňky $7 D002478

650    02

$a ženské pohlaví $7 D005260

650    02

$a lidé $7 D006801

650    02

$a mužské pohlaví $7 D008297

650    02

$a lidé středního věku $7 D008875

650    02

$a monocyty $x imunologie $x účinky léků $7 D009000

650    02

$a messenger RNA $x genetika $7 D012333

650    02

$a polymerázová řetězová reakce s reverzní transkripcí $x metody $7 D020133

650    02

$a proteiny S100 $x farmakologie $x krev $7 D009418

650    02

$a stupeň závažnosti nemoci $7 D012720

650    02

$a TNF-alfa $x antagonisté a inhibitory $x biosyntéza $x genetika $7 D014409

650    02

$a upregulace $x imunologie $x účinky léků $7 D015854

700    1_

$a Grigorian, Mariam

700    1_

$a Hulejová, Hana $7 xx0077461

700    1_

$a Vencovský, Jiří, $d 1953- $7 jo20000080529

700    1_

$a Pavelka, Karel, $d 1954- $7 jn99240000847

700    1_

$a Klingelhofer, Jorg

700    1_

$a Gay, Steffen

700    1_

$a Neidhart, Michel

700    1_

$a Brabcová, Hana $7 xx0128498

700    1_

$a Suchý, David, $d 1970- $7 xx0111581

700    1_

$a Šenolt, Ladislav, $d 1976- $7 xx0056558

773    0_

$t Rheumatology $p Rheumatology (Oxford) $g Roč. 48, č. 12 (2009), s. 1590-1594 $x def $w MED00011379

773    0_

$p Rheumatology (Oxford) $g 48(12):1590-4, 2009 Dec

910    __

$a ABA008 $b x $y 4 $z 0

990    __

$a 20120319150914 $b ABA008

991    __

$a 20140730110147 $b ABA008

999    __

$a ok $b bmc $g 902376 $s 766059

BAS    __

$a 3

BMC    __

$a 2009 $b 48 $c 12 $d 1590-1594 $i def $m Rheumatology $x MED00011379

GRA    __

$a NR9082 $p MZ0

LZP    __

$a 2012-1Q10/